2018 American Transplant Congress
Single-Dose Basiliximab Induction in Liver Transplant Recipients with Delayed CNI Initiation
Liver transplant recipients (LTR) with peri-operative renal injury benefit from a delayed CNI protocol using basiliximab (IL2RA) induction to reduce early CNI exposure. Existing literature…2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…2018 American Transplant Congress
Outcomes in Liver Transplant Patients on Renal Sparing Protocol
As liver transplant outcomes have improved, long term native kidney function has taken a critical role in patient survival. Calcineurin inhibitors (CNIs), such as Tacrolimus…2018 American Transplant Congress
Overexpression of BAX, NOL3, and XIAP Apoptotic Genes Participates in Calcineurin Inhibitors Nephrotoxicity: New Insights into Chronic Allograft Dysfunction
Introduction: Calcineurin inhibitors toxicity (CNIT) is a factor that limit the outcome of renal transplantation graft. The hypoxia causes histological data as nodular hyalinosis, hyalinosis,…2018 American Transplant Congress
Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients
Duke University Hospital, Durham, NC.
Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…2018 American Transplant Congress
The Providers Can't Let Go! An Analysis of an RN Driven Tacrolimus Dose Adjustment Protocol
Introduction: Tacrolimus (FK) dose adjustment is frequently performed by non-MD staff. Standard protocols to evaluate the ability of non-providers to maintain pts within a goal…2018 American Transplant Congress
Genome-Wide Association Study of Tacrolimus Dose in Pediatric Solid Organ Transplant Recipients in the CNTRP POSITIVE Study
PURPOSE: There are significant challenges in achieving therapeutic tacrolimus (Tac) concentrations after transplant. We explored variants associated with tacrolimus dose requirements in pediatric solid organ…2017 American Transplant Congress
Conversion from Calcineurin Inhibitor to Sirolimus in Kidney Transplantation Recipients with Malignancy.
Nephrology, Asan Medical Center, Seoul, Republic of Korea
Background: Kidney transplant recipients are at an increased risk of malignancy for various reasons, such as the chronic use of calcineurin inhibitor (CNI). Sirolimus (SRL),…2017 American Transplant Congress
Efficacy of Calcineurin Inhibitors Transferring to Rapamycin in Live Kidney Transplantation from Old Donors to Young Recipients.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background Calcineurin inhibitor(CNI) nephrotoxicity is one of the major reasons for chronic allograft injury in live kidney transplantation from old donors to young recipients. Therefore…2017 American Transplant Congress
Influence of Tacrolimus Metabolism Rate on Patients' Survival After Renal Transplantation.
Introduction: Tacrolimus (Tac) is an integral part of the immunosuppressive regimen after renal transplantation (RTx). A fast Tac metabolism rate defined as the Tac blood…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 16
- Next Page »